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Abstract Background:
Inhibition of the nuclear factor kappa beta (NF-κβ) pathway has been proposed as a therapeutic target due
to its key role in the expression of pro-inflammatory genes, including pro-inflammatory cytokines,
chemokines, and adhesion molecules. Caffeic acid phenethyl ester (CAPE) is a naturally occurring anti-
inflammatory agent, found in propolis, and has been reported as a specific inhibitor of NF-κβ. However,
the impact of CAPE on levels of myeloperoxidases (MPO) and pro-inflammatory cytokines during
inflammation is not clear. The aims of this study were to investigate the protective efficacy of CAPE in the
mouse model of colitis and determine its effect on MPO activity, pro-inflammatory cytokines levels, and
intestinal permeability.
Method:
Dextran sulphate sodium was administered in drinking water to induce colitis in C57/BL6 mice before
treatment with intraperitoneal administration of CAPE (30 mg kg−1 day−1). Disease activity index (DAI)
score, colon length and tissue histology levels of MPO, pro-inflammatory cytokines, and intestinal
permeability were observed.
Results:
CAPE-treated mice had lower DAI and tissue inflammation scores, with improved epithelial barrier
protection and significant reduction in the level of MPO and pro-inflammatory cytokines.
Conclusion:
Our results show that CAPE is effective in suppressing inflammation-triggered MPO activity and pro-
inflammatory cytokines production while enhancing epithelial barrier function in experimental colitis.
Thus, we conclude that CAPE could be a potential therapeutic agent for further clinical investigations for
treatment of inflammatory bowel diseases in humans.
Keywords (separated by '-') Inflammatory bowel diseases - Colitis - Natural - Nuclear factor kappa beta - Pro-inflammatory cytokines -
Intestinal permeability
Footnote Information Electronic supplementary material The online version of this article (doi:10.1007/s10787-017-0364-x)
contains supplementary material, which is available to authorized users.
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8 Abstract
9 Background Inhibition of the nuclear factor kappa beta
10 (NF-jb) pathway has been proposed as a therapeutic target
11 due to its key role in the expression of pro-inﬂammatory
12 genes, including pro-inﬂammatory cytokines, chemokines,
13 and adhesion molecules. Caffeic acid phenethyl ester
14 (CAPE) is a naturally occurring anti-inﬂammatory agent,
15 found in propolis, and has been reported as a speciﬁc
16 inhibitor of NF-jb. However, the impact of CAPE on
17 levels of myeloperoxidases (MPO) and pro-inﬂammatory
18 cytokines during inﬂammation is not clear. The aims of this
19 study were to investigate the protective efﬁcacy of CAPE
20 in the mouse model of colitis and determine its effect on
21 MPO activity, pro-inﬂammatory cytokines levels, and
22 intestinal permeability.
23 Method Dextran sulphate sodium was administered in
24 drinking water to induce colitis in C57/BL6 mice before
25 treatment with intraperitoneal administration of CAPE
26 (30 mg kg
-1 day-1). Disease activity index (DAI) score,
27 colon length and tissue histology levels of MPO, pro-in-
28 ﬂammatory cytokines, and intestinal permeability were
29 observed.
30Results CAPE-treated mice had lower DAI and tissue
31inﬂammation scores, with improved epithelial barrier pro-
32tection and signiﬁcant reduction in the level of MPO and
33pro-inﬂammatory cytokines.
34Conclusion Our results show that CAPE is effective in
35suppressing inﬂammation-triggered MPO activity and pro-
36inﬂammatory cytokines production while enhancing
37epithelial barrier function in experimental colitis. Thus, we
38conclude that CAPE could be a potential therapeutic agent
39for further clinical investigations for treatment of inﬂam-
40matory bowel diseases in humans.
41
42Keywords Inﬂammatory bowel diseases  Colitis 
43Natural  Nuclear factor kappa beta 
44Pro-inﬂammatory cytokines  Intestinal permeability
45
46Introduction
47Inﬂammatory bowel disease (IBD) is an idiopathic disor-
48der, generally categorised as either Crohn’s disease (CD) or
49ulcerative colitis (UC) (Neurath 2014; Ford et al. 2011).
50There is no therapeutic cure for IBD and the current disease
51management strategies possess several drawbacks. For
52example, immunomodulatory agents, such as azathioprine
53and 6-mercaptopurine, cause bone marrow depletion and
54damage to both white blood cell and hepatic cell popula-
55tions. Furthermore, results from recent clinical trials
56conﬁrm that azathioprine is ineffective in UC (Ardizzone
57et al. 2006; Kamath et al. 2016; O’Connor et al. 2010) and
58sulfasalazine causes ruptures in liver tissue and decreases
59platelets count in blood (de Abajo et al. 2004; Rubin 1994).
60Furthermore, pulmonary disorders are reported in IBD
61patients treated with chimeric monoclonal antibodies, such
62as inﬂiximab (Patel et al. 2016).
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63 The clinical symptoms of IBD range from episodes of
64 relapse and remission with mild inﬂammation and dis-
65 comfort to a chronic ulcerative disease requiring surgical
66 removal of the inﬂamed gut. The current therapeutic
67 strategies for IBD are generally limited, but recent clinical
68 advancement has occurred in immunotherapy using mon-
69 oclonal antibodies. This approach is directed against
70 inﬂammatory mediators, such as TNF-a (Targan 2006;
71 Subramanian et al. 2017; Gecse and Lakatos 2017; Chan
72 and Ng 2017). However, these biological agents are
73 expensive and result in severe side effects and life threat-
74 ening complications (Cote-Daigneault et al. 2015; Blonski
75 and Lichtenstein 2006; Clarke and Regueiro 2012; Cohen
76 and Thomas 2006). Hence, there is a need in the ﬁeld of
77 IBD therapy to develop new therapeutics, which are
78 effective, safe, and economical. One way to achieve this is
79 investigation into the anti-inﬂammatory effect of natural
80 compounds and understanding their mechanism of action.
81 Lack of speciﬁcity and the encumbrance of severe side
82 effects necessitate further investigation into effective and
83 safer options for treating IBD (Pichai and Ferguson 2012),
84 which is the aim of this current study.
85 Colonic specimens from UC patients display overex-
86 pression of transcription factor nuclear factor kappa beta
87 (NF-jb) (Atreya et al. 2008). NF-jb is up regulated by
88 TNF-a, interleukin (IL), interferon, chemokines, and DNA
89 damaging agents during the inﬂammatory phase. Similar
90 effects are observed following exposure to lipopolysac-
91 charide derived from bacterial cell wall components
92 (Lawrence 2009b; Xavier and Podolsky 2007). In UC,
93 levels of inﬂammatory mediators, such as TNF-a, inter-
94 leukins, and interferons, increase due to the over
95 stimulation of NF-jb during inﬂammation (Schreiber et al.
96 1998). It is feasible, therefore, that inhibition of NF-jb
97 may be of therapeutic beneﬁt in UC, which forms the
98 hypothesis of our current work.
99 Novel pharmacological inhibitors of NF-jb are cur-
100 rently available, but these compounds inﬂect toxicity and
101 severe side effects in humans. Hence, we have selected
102 caffeic acid phenethyl ester (CAPE), a phenolic constituent
103 derived from honeybee propolis and shown in Fig. 1, for
104 further study. It possesses no known adverse side effects
105 (Tolba et al. 2014; Liao et al. 2003). CAPE possesses
106 potent anti-inﬂammatory properties, which are attributed to
107its selective inhibition of NF-jb. Recently, CAPE has been
108reported to inhibit other relevant pathways, such as MAPK
109and PI3K (Natarajan et al. 1996; Ozturk et al. 2012; Lin
110et al. 2013; Pramanik et al. 2013; Cho et al. 2014). CAPE
111represses translocation of NF-jb, either by inhibition of
112Ijb degradation or by blocking of NF-jb and DNA binding
113(Wang et al. 2010; Bezerra et al. 2012). It has been
114reported that inﬂammatory markers, such as INF-!, IL-6,
115IL-b, TNF-a, and IL-10, cause degradation of Ijb, which
116results in induced overexpression of NF-jb (Lang et al.
1172004). CAPE inhibits this overexpression of NF-jb via
118prevention of degradation of Ijb (Wang et al. 2010; Lee
119et al. 2008).
120The most recent evaluation of the anti-inﬂammatory
121activity of CAPE has been limited to either cell culture
122models or rat models of 2,4,6-trinitrobenzenesulfonic acid-
123peptidoglycan polysaccharide-induced UC (Armutcu et al.
1242015; Ek et al. 2008; Fitzpatrick et al. 2001; Kim et al.
1252013). However, the pathophysiological mechanism, such
126as macroscopic, microscopic changes in the colon and
127effect on pro-inﬂammatory cytokine levels, and mucosal
128barrier function, by which CAPE exerts its anti-inﬂam-
129matory activity, have not been fully explored (Fitzpatrick
130et al. 2001; Michaluart et al. 1999; Ek et al. 2008; Cooper
131et al. 1993). Hence, the activity of CAPE has not been
132studied in relevant in vivo models, which are physiologi-
133cally more representative of the human disease (Chassaing
134et al. 2014a). Thus, the main aspect of this study, which
135differentiates it from the previous work, is assessment of
136the activity of CAPE on the colon at macroscopic and
137microscopic levels, its effect on MPO and pro-inﬂamma-
138tory cytokine levels and altered mucosal permeability in a
139mouse model of colitis, which is physiologically relevant to
140human disease (Tambuwala et al. 2015). The ﬁndings of
141this study will provide an insight into the anti-inﬂammatory
142efﬁcacy of CAPE during colitis in terms of changes in the
143levels of the disease activity index (DAI) score, colon
144MPO, pro-inﬂammatory cytokines, and epithelial barrier
145function.
146Materials and methods
147Materials
148Caffeic acid phenethyl ester (97%) was purchased from
149Sigma-Aldrich Ltd. (Dorset, UK) and dextran sodium
150sulphate (DSS) was procured from MP Biomedicals
151(Bedford, UK) (molecular weight 36,000–50,000). CAPE
152was administered by IP injection at a dose of 30 mg kg
-1
153on a daily basis for 7 days. The injection was prepared by
154dissolving CAPE (1.0 mg) in 1.0 ml of sterile aqueous
155solution containing 25% PEG 200.Fig. 1 Chemical structure of caffeic acid phenethyl ester (CAPE)
M. N. Khan et al.
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156 Dextran sodium sulphate model of induced colitis
157 For DSS colitis-induced experiments, 12-week-old C57BL/
158 6 female mice were used (Charles River, UK). The Ulster
159 University Animal Research Ethics Committee and UK
160 Home Ofﬁce approved all procedures described, under
161 Project license (PL2768).
162 Colitis was induced by administering 2.5% w/v DSS in
163 drinking water over a period of 7 days. The DAI score was
164 used to record morphological changes, such as weight loss,
165 stool consistency, and presence of blood in faeces. On
166 termination of the experiment, mice were sacriﬁced by
167 cervical dislocation (Egger et al. 2000; Okayasu et al.
168 1990). The isolated colon was excised, washed in PBS, and
169 laid ﬂat on moist tissue to measure its length. Sections,
170 approximately 1.0 cm, of excised colonic tissue were ﬁxed
171 in 10% paraformaldehyde (pH 7.4; phosphate-buffered
172 saline) and embedded in parafﬁn. Sections (4 lm) were cut
173 and stained with hematoxylin and eosin. Histologic
174 assessment and scoring of colon tissue sections were car-
175 ried out in a blinded fashion based on previously deﬁned
176 parameters (Sutherland et al. 1987). All tissue slides were
177 imaged using light a microscopy at 59 and 109
178 magniﬁcations.
179 Colon cytokine and myeloperoxidases measurements
180 Post-mortem colon tissue was homogenised using a method
181 adapted from processing lung tissue (Mangan et al. 2006).
182 Levels of pro-inﬂammatory cytokines, such as INF-c, IL-6,
183 IL1-b, TNF-a, and IL-10, were detected using V-Plex
184 Assay Plates (Meso Scale Diagnostics; Rockville, MD,
185 USA) and assayed as per the manufacturer’s protocol.
186 MPO activity was detected using o-phenylenediamine
187 dihydrochloride as substrate and the data were interpolated
188 from an MPO standard curve (Sigma). Levels of cytokines
189 and MPO were expressed as pg per mg or U per mg,
190 respectively, relative to colon protein (Cummins et al.
191 2008).
192 Assessment of NF-jb activation in colon tissue
193 Colon tissue was homogenised and lysate then analysed for
194 NF-jb/p65 levels using a Nuclear Extraction kit (Ac-
195 tiveMotif, Carlsbad, USA) in accordance with the
196 manufacturer’s protocol (Lin et al. 2014).
197 In vivo intestinal permeability measurements
198 Mice were exposed to 7 days of DSS treatment, which was
199 followed by standard oral gavage of ﬂuorescein isothio-
200 cyanate (FITC)-labelled dextran (4 kDa) at a dose of
201 0.6 mg g
-1 of body weight. Mice were euthanised 4 h later
202and blood removed by cardiac puncture. Plasma was sep-
203arated and FITC levels in plasma determined by
204ﬂuorometry (Tambuwala et al. 2010).
205Statistical analysis
206Results were expressed as mean ± standard error of the
207mean (SEM) for a series of experiments. Data were
208assumed to be normally distributed and statistical analyses
209were carried out using Prizm GraphPad V6 software
210(GraphPad, San Diego, CA, USA). A paired t test was used
211for comparisons of paired treatments between two groups,
212unpaired t tests for comparisons of unpaired treatments
213between two groups, and one-way ANOVA using Bon-
214ferroni multiple comparisons tests for treatments of three
215groups or more. P values B0.05 were considered to be
216signiﬁcant.
217Ethical considerations
218The Ulster University Animal Research Ethics Committee
219and UK Home Ofﬁce approved all procedures described,
220under Project license (PL2768). Severity levels were gra-
221ded as mild by the UK home ofﬁce.
222Results
223CAPE ameliorates disease in DSS-induced colitis
224It has been reported by us and several researchers that
225colitis is a collection of symptoms, such as weight loss,
226diarrhoea, and blood in faeces, collectively described by
227the DAI and shortening of colon length (Ogawa et al. 2004;
228Taghipour et al. 2016; Chassaing et al. 2014b; Chen et al.
2292007). To study the protective effect of CAPE on mice
230with DSS-induced colitis, we recorded the weight of each
231mouse in all groups daily for 7 days. Figure 2a shows
232signiﬁcantly (P\ 0.001) lowered weight loss in
233DSS ? CAPE-treated mice when compared to the DSS-
234only group. Similarly, Fig. 2b shows that mice in the DSS-
235alone group had the highest DAI score, which conﬁrmed
236the development of colitis. Mice treated with CAPE
237showed a signiﬁcantly (P\ 0.01) lower DAI score, when
238comparison is made to the DSS-only group. This ﬁnding
239suggests that CAPE was protecting mice against weight
240loss and the occurrence of diarrhoea and appearance of
241blood in faeces during DSS-induced colitis.
242Shortening of the colon is one of the clinical signs of
243colitis (Tambuwala et al. 2015). Figure 3a shows repre-
244sentative image from the colon of a healthy mouse with
245well-formed stool pellets. In contrast, there were no formed
246stools and blood observed in the colon of mice treated with
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247 DSS alone. However, semi-formed stools and no blood
248 were visible in the colon of mouse treated with CAPE. A
249 graphical presentation of the average colon length of each
250 group is shown in Fig. 3b. It was observed that there was
251 signiﬁcant (P\ 0.001) reduction in colon length in mice
252 treated with DSS alone when compared to the healthy
253 control and DSS ? CAPE-treated mice. Thus, CAPE
254 treatment attenuated the impact of DSS on colon length
255 reduction and also assisted stool formation.
256Histological examination of colon tissue conﬁrmed that
257DSS treatment caused extensive colonic damage with lose
258of epithelium and collapse of crypt structure. This was
259accompanied by oedema and inﬁltration of inﬂammatory
260neutrophils (Fig. 4a). In contrast, there was a marked
261reduction in severity of DSS-induced colon injury in
262CAPE-treated mice. The crypt architecture showed that no
263ulceration or evidence of oedema, lesser degree of inﬁl-
264tration of inﬂammatory cells, and neutrophils were
Fig. 2 Lowered percentage weight loss and DAI score in mice
treated with CAPE during DSS-induced colitis. a Percentage weight
loss was assessed in mice treated with DSS-alone (red line), DSS and
CAPE (green line), and no DSS healthy mice (black line). b Disease
activity index was assessed in mice treated with DSS-alone (red line),
DSS and CAPE (green line), and no DSS healthy mice (black line)
over 7 days. Each control and experimental group contained a
minimum of 5–6 individual mice (P\ 0.001–0.01)
Fig. 3 CAPE treatment is effective in protecting gross anatomy and
colon length. a Gross appearance of the colonic anatomy shows the
effect of CAPE on DSS-induced colon shortening and formation of
fecal pellets. b Colon length was measured at post-mortem autopsy
(P\ 0.001). N = 5–6 mice per group
M. N. Khan et al.
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265 observed in the colon histology of mice receiving CAPE
266 treatment (Fig. 4a). The blinded histological scoring of
267 colon tissue histology revealed a signiﬁcant reduction of
268 damage in the colon of CAPE-treated mice relative to
269 healthy control mice (P\ 0.001; Fig. 4b). To conﬁrm that
270 CAPE downregulated the NF-jb pathway in DSS-induced
271 colitis, we assessed the levels of p65 in colon tissue. There
272 was a marked increase in the level of p65 in DSS-alone
273 group and the mice treated with CAPE showed a signiﬁcant
274 reduction in the level of p65 (Supplementary Figure 1).
275 We next investigated the impact of CAPE treatment of
276 the expression of markers of colonic inﬂammation that are
277 increased in mice exposed to DSS. DSS-alone control mice
278 showed a signiﬁcant increase in MPO activity, a marker for
279 inﬂammation, and leukocyte inﬁltration (P\ 0.01;
280 Fig. 5a). However, exposure of CAPE-treated mice to DSS
281 did not result in increased colon MPO levels (Fig. 5a). We
282 also noted that colonic levels of pro-inﬂammatory cytoki-
283 nes, such as INF-c, IL6, IL1-b, TNF-a, and IL10 (Fig. 5b–
284 e), were signiﬁcantly (P\ 0.001) increased in mice with
285 DSS-induced colitis, as compared to healthy mice. Co-
286 administration of CAPE resulted in small increases in INF-
287 c, IL1-b, TNF-a, and IL10, which were not signiﬁcantly
288 different from that of the healthy control. Thus, the DSS-
289 induced colitis resulted in an increase in MPO, INF-c, IL6,
290 IL1-b, TNF-a, and IL10. All were diminished signiﬁcantly
291 in CAPE-treated mice (P\ 0.01–0.001). Although IL-10 is
292 known to play a protective role in colitis, we observed a
293 small decrease in IL-10 levels in mice treated with CAPE,
294which was expected as CAPE is known to lower the levels
295of IL-10 (Sy et al. 2011). Furthermore, treatment of mice
296with CAPE alone had no effects on MPO, INF-c, IL6, IL1-
297b, and TNF-a (data not shown).
298Enhanced epithelial barrier function in mice treated
299with CAPE
300To investigate the effect of CAPE treatment on the
301intestinal epithelial integrity, in vivo barrier function was
302measured in healthy mice, mice exposed to DSS and mice
303co-treated with CAPE and DSS. An oral dose of FITC-
304dextran was administered to mice on the last day of DSS
305exposure. Four hours later, FITC levels in plasma were
306determined as a measure of intestinal permeability. The
307DSS-only group of mice exhibited a signiﬁcant increase in
308intestinal permeability, which was reﬂected by an increased
309appearance of FITC in plasma. This effect was markedly
310diminished in mice treated with CAPE (Fig. 6a;
311P\ 0.001), indicating that co-treatment with CAPE during
312DSS-induced colitis reduces the leakiness of the colon and
313maintains the epithelial barrier function.
314Discussion
315The previous studies have indicated that CAPE is an
316effective inhibitor of NF-jb and related cytokines
317in vitro, and also has the ability induce apoptosis in
Fig. 4 Improved colon histological outcome in mice treated with CAPE. a Representative histological images of colonic tissue showing the
effect of CAPE treatment (H&E staining). b Histological scores of sections scored blinded. N = 5–6 mice per group (P\ 0.001)
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318 inﬂammatory cells (Fitzpatrick et al. 2001). In our current
319 study, we have shown for the ﬁrst time that CAPE sig-
320 niﬁcantly ameliorates the severity of the disease in a
321 mouse model of UC.
322One of the initial events that occur during the onset of
323IBD is disruption of the intestinal epithelial barrier func-
324tion. This dysfunction leads to unwanted movement of
325luminal antigenic material into the lamina propria. This is
Fig. 5 Effect of CAPE on expression of pro-inﬂammatory mediators. The colon tissue homogenates analysed for aMPO, b INF-!, c IL-6, d IL-
b, e TNF-a, and f IL-10. N = 5–6 mice per group (P\ 0.001)
M. N. Khan et al.
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326 followed by activation of mucosal immune cells and trig-
327 gering of an inﬂammatory response. It has been suggested
328 that one of the critical events in the development of
329 inﬂammation in the intestine could be the regulation of
330 intestinal epithelial cell apoptosis (Cummins et al. 2008;
331 Tambuwala et al. 2010). In cases of chronic inﬂammation
332 during IBD, constant intestinal epithelial cell apoptosis
333 could lead the loss of the epithelial barrier, which will
334 result in spread of inﬂammation, resulting in increased
335 severity of the disease. This creates an imbalance in the
336 innate and adaptive immunity of the gut (Nenci et al. 2007;
337 Zaph et al. 2007).
338 In the present work, we have shown for the ﬁrst time
339 that CAPE, a potent inhibitor NF-jb, is profoundly pro-
340 tective in an in vivo mouse model of acute colonic
341 inﬂammation. Although we hypothesise that the protective
342 effects of CAPE are mediated through the inhibition of the
343 over activation of the NF-jb pathway, we cannot exclude
344 the possibility of NF-jb independent mechanisms of
345 action, such as inhibition of hydroxylases and activation of
346 hypoxia inducible pathways (Cummins et al. 2008).
347 However, several researchers have indicated that the NF-
348 jb pathway plays an important role during intestinal
349 inﬂammation (Wei and Feng 2010; Buhrmann et al. 2011;
350 Lawrence 2009a; Fitzpatrick et al. 2001) and inhibition of
351 this pathway targets pro-inﬂammatory cytokines, such as
352 interferons and tumour necrosis factor alpha. These are
353 known to play key role during the development and
354progression of UC (Baird et al. 2016; Bishop et al. 2014;
355Ferrari et al. 2016).
356CAPE treatment signiﬁcantly ameliorated the severity of
357disease after acute DSS exposure in all parameters studied,
358including weight loss (Fig. 2a), clinical DAI score
359(Fig. 2b), reduction of colon length, and appearance of
360blood in faeces (Fig. 3a, b). A marked improvement in
361colon histology was observed (Fig. 4a), together with
362improved blinded inﬂammation scores (Fig. 4b). In the
363murine model of DSS-induced colitis, the increase in MPO
364and pro-inﬂammatory cytokines occurred after the disrup-
365tion to the intestinal barrier, indicating that compromised
366barrier function results in progression inﬂammation.
367CAPE-treated mice did not have increased MPO (Fig. 5a)
368and only small increase in other pro-inﬂammatory cytoki-
369nes (Fig. 5b–f), suggesting that CAPE treatment prevented
370the damage to colon epithelial cells caused by DSS and
371helps in maintaining the epithelial barrier function, which
372is evident by reduced permeability of FITC in mice treated
373with CAPE (Fig. 6). However, whether improved epithelial
374barrier function or indeed lowered cytokine expression is
375the cause or consequence of the protective effects of CAPE
376remains to be elucidated. This critical question will be the
377topic of further investigations.
378In mice treated with CAPE, in the absence of DSS
379exposure, there were no alterations in MPO or cytokines in
380the colon and no alterations in colon histology or length.
381This conﬁrms that in the acute 6-day treatment regimen
382used in this study, CAPE did not alter physiologic
383inﬂammation in normal tissue, but instead suppressed
384inﬂammation in the colon when occurred due to DSS-in-
385duced disruption of the barrier function.
386In this study, we have observed that there was an
387increase in NF-jb activity in the colon of mice treated with
388DSS and that CAPE downregulates this increase, thereby
389exerting a protective event in a mouse model of UC. Since
390CAPE is a natural compound, with no known side effects
391(Tambuwala 2016), its therapeutic beneﬁts are obvious and
392desirable when measured up against over other novel
393compounds with pro-tumorigenic effects; such as DMOG,
394which have also shown to be protective in experimental
395colitis (Cummins et al. 2008). The ﬁndings of this work
396indicate that CAPE can be used an effective ﬁrst-line
397treatment for patients with UC, improving intestinal barrier
398function and halting the progression of disease, whilst
399promoting mucosal healing. The next stage of our work
400will focus on two elements, namely (1) development of
401nanoparticle-based colonic drug delivery of CAPE, which
402could allow for local delivery of the drug to inﬂamed tissue
403to ensure effective therapeutic outcomes using a lower dose
404and (2) identiﬁcation of the NF-jb subunit most affected
405by CAPE.
Fig. 6 Reduced epithelial permeability in mice treated with CAPE.
Mice treated with DSS with or without CAPE (30 mg/kg) IP and
healthy mice were administered 4 kDa-FITC-labelled dextran orally,
and serum levels of FITC were assessed. Each control and experi-
mental group contains 5–6 mice (P\ 0.001)
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